Dose-dense adjuvant chemotherapy in patients with HER2-low early breast cancer: An exploratory analysis of the GIM2 trial. Cost consequence model of the MammaPrint (70-gene signature) and 21-gene ...
Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology Three models for yearly time series predictions were built: autoregressive integrated ...
(Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Proteograph ® Product Suite, has been selected as the mass spectrometry-based proteomic ...
The probability of overall survival after 1, 5, and 10 years was predicted by a nomogram model, which found that worse Surveillance, Epidemiology, and End Results (SEER) stage was associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results